PMID- 24636699
OWN - NLM
STAT- MEDLINE
DCOM- 20141210
LR  - 20220409
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 84
IP  - 2
DP  - 2014 May
TI  - The oncogenic role of PKCiota gene amplification and overexpression in Chinese 
      non-small cell lung cancer.
PG  - 190-5
LID - S0169-5002(13)00394-2 [pii]
LID - 10.1016/j.lungcan.2013.08.029 [doi]
AB  - BACKGROUND: The atypical protein kinase C isozyme iota (PKCiota) has been 
      proposed as an oncogene based on its transformation property and amplification 
      identified in Caucasian non-small cell lung cancer (NSCLC) patients. Because the 
      geography difference of some genetic aberrance such as EGFR mutations between 
      Caucasian and Asian NSCLC patients has been identified previously, it is 
      important to know whether the PKCiota amplification also occurs in Asian NSCLC 
      patients. METHODS: The PKCiota gene copy number changes and protein expression in 
      Chinese patients samples were detected by fluorescence in situ hybridization 
      (FISH) and immunohistochemistry (IHC), respectively. Logistic regression was used 
      to assess the association of PKCiota expression with clinicopathological 
      parameters. siRNA-mediated gene silencing was applied to demonstrate the role of 
      PKCiota in promoting cell growth in PKCiota gene amplified and protein 
      overexpressed cancer cells. RESULTS: The result showed that PKCiota gene was 
      amplified in 20.2% (24/119) of the tested primary tumor samples from Chinese 
      NSCLC patients. Interestingly this gene amplification was highly enriched in 
      squamous NSCLC patients (37.1%, 23/62). Further IHC analysis indicated that 
      PKCiota protein was highly expressed (IHC score 2+ and 3+) in 91.6% (109/119) of 
      Chinese NSCLC tumors. Moreover, the PKCiota gene amplification was also 
      correlated with gender, subtype and distant metastasis. Knockdown of PKCiota gene 
      in the PKCiota gene amplified and protein overexpressed cells led to significant 
      growth inhibition. CONCLUSION: Taken together, our data demonstrate that PKCiota 
      is a potential oncogene and therapeutic target in Chinese NSCLC.
CI  - Copyright (c) 2014. Published by Elsevier Ireland Ltd.
FAU - Luo, Qingquan
AU  - Luo Q
AD  - Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai 
      Jiaotong University, Shanghai, China.
FAU - Tang, Lili
AU  - Tang L
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Lin, Hao
AU  - Lin H
AD  - Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai 
      Jiaotong University, Shanghai, China.
FAU - Huang, Jia
AU  - Huang J
AD  - Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai 
      Jiaotong University, Shanghai, China.
FAU - Zhang, Tianwei
AU  - Zhang T
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Liu, Yuanjie
AU  - Liu Y
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Wang, Jia
AU  - Wang J
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Zhan, Ping
AU  - Zhan P
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Yin, Xiaolu
AU  - Yin X
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Su, Xinying
AU  - Su X
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Ji, Qunsheng
AU  - Ji Q
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China.
FAU - Yu, Dehua
AU  - Yu D
AD  - Innovation Center China, AstraZeneca, Shanghai, 201203, China. Electronic 
      address: derek.yu@astrazeneca.com.
FAU - Xu, Lin
AU  - Xu L
AD  - Department of Thoracic Surgery, Nanjing Medical University affiliated Cancer 
      Hospital, Nanjing 210009, China. Electronic address: xulin83@vip.sina.com.
LA  - eng
PT  - Journal Article
DEP - 20130908
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Isoenzymes)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 2.7.11.13 (protein kinase C lambda)
SB  - IM
MH  - Adenocarcinoma/enzymology/*genetics/secondary
MH  - Carcinoma, Non-Small-Cell Lung/enzymology/*genetics/secondary
MH  - Cell Line, Tumor
MH  - China
MH  - Female
MH  - *Gene Amplification
MH  - Gene Expression
MH  - Humans
MH  - Isoenzymes/*genetics/metabolism
MH  - Lung Neoplasms/enzymology/*genetics/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Squamous Cell/enzymology/*genetics/secondary
MH  - Oncogenes
MH  - Protein Kinase C/*genetics/metabolism
MH  - Sex Distribution
OTO - NOTNLM
OT  - Amplification
OT  - Chinese NSCLC
OT  - Overexpression
OT  - PKCiota
EDAT- 2014/03/19 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/03/19 06:00
PHST- 2013/05/21 00:00 [received]
PHST- 2013/07/26 00:00 [revised]
PHST- 2013/08/31 00:00 [accepted]
PHST- 2014/03/19 06:00 [entrez]
PHST- 2014/03/19 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S0169-5002(13)00394-2 [pii]
AID - 10.1016/j.lungcan.2013.08.029 [doi]
PST - ppublish
SO  - Lung Cancer. 2014 May;84(2):190-5. doi: 10.1016/j.lungcan.2013.08.029. Epub 2013 
      Sep 8.